Rollout of Powerful New HIV Prevention Tool in Lower Income Countries Gets a Boost

Rollout of powerful new HIV prevention tool in lower income countries gets a boost

Global Fund and U.S. government plan to make injectable lenacapavir available to 3 million people by 2028

Rwanda included in global rollout of long-acting HIV prevention drug - Rwanda Dispatch News Agency

Rwanda is among countries set to receive a new long-acting HIV prevention injection as part of a global expansion led by the United States and the Global Fund to Fight AIDS, Tuberculosis and Malaria. The drug, lenacapavir, is an injectable form of pre-exposure prophylaxis (PrEP) developed by Gilead Sciences. It is designed to help prevent […] The post Rwanda included in global rollout of long-acting HIV prevention drug appeared first on Rwanda D…

One Million More People To Get HIV ‘Miracle’ Drug Lenacapavir As US, Global Fund Expand Access

The United States and the Global Fund will support three million people to get lenacapavir, the twice-a-year HIV injection that is almost 100% successful in preventing transmission of the virus – a million more than their previous commitment. Jeremy Lewin, US Under Secretary of State for Foreign Assistance, Humanitarian Affairs and Religious Freedom at the […]

PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

U.S. and Global Fund Expand Commitment to Long-Acting HIV Prevention as Country Rollout of Lenacapavir Accelerates

The United States and the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today announced an expanded commitment to scale up access to long-acting lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP), aiming to reach an additional 1 million people over the next three years. Building on the original commitment, this brings the total joint ambition to 3 million people reached with LEN through 2028.